Cargando…
Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was design...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316769/ https://www.ncbi.nlm.nih.gov/pubmed/25699020 http://dx.doi.org/10.3389/fendo.2015.00011 |
_version_ | 1782355614609965056 |
---|---|
author | Vilar, Lucio Albuquerque, José Luciano Gadelha, Patrícia Sampaio Rangel Filho, Frederico Siqueira, Aline Maria C. da Fonseca, Maíra Melo Viana, Karoline Frazão Gomes, Barbara Sales Lyra, Ruy |
author_facet | Vilar, Lucio Albuquerque, José Luciano Gadelha, Patrícia Sampaio Rangel Filho, Frederico Siqueira, Aline Maria C. da Fonseca, Maíra Melo Viana, Karoline Frazão Gomes, Barbara Sales Lyra, Ruy |
author_sort | Vilar, Lucio |
collection | PubMed |
description | Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was designed to address this topic and to try to identify possible predictor factors. Among 180 patients with prolactinomas on CAB therapy, the authors selected those who fulfilled very strict criteria, particularly additional CAB therapy for at least 2 years, normalization of serum prolactin (PRL) levels following CAB restart, no tumor remnant >10 mm, no previous pituitary radiotherapy or surgery; and current CAB dose ≤1.0 mg/week. Recurrence was defined as an increase of PRL levels above the upper limit of normal. A total of 34 patients (70.6% female) treated with CAB for 24–30 months were recruited. Ten patients (29.4%) remained without evidence of recurrence after 24–26 months of follow-up. Twenty-four patients (70.6%) recurred within 15 months (75% within 12 months) after drug withdrawal and ~80% were restarted CAB. Median time to recurrence was 10.5 months (range, 3–15). Despite overlapping values, non-recurring patients had significantly lower mean PRL levels before withdrawal. Moreover, the recurrence rate was lower in subjects without visible tumor on pituitary magnetic resonance imaging (MRI) than in those with small remnant tumor (60 vs. 79%), though the difference was not statistically significant (P = 0.20). No other characteristic could be identified as a predictor of successful CAB discontinuation. In conclusion, a second attempt of CAB withdrawal after two additional years of therapy may be successful, particularly in patients with lower PRL levels and no visible tumor on pituitary MRI. Close monitoring of PRL level is mandatory, especially within the first year after withdrawal, where most recurrences are detected. |
format | Online Article Text |
id | pubmed-4316769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-43167692015-02-19 Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? Vilar, Lucio Albuquerque, José Luciano Gadelha, Patrícia Sampaio Rangel Filho, Frederico Siqueira, Aline Maria C. da Fonseca, Maíra Melo Viana, Karoline Frazão Gomes, Barbara Sales Lyra, Ruy Front Endocrinol (Lausanne) Endocrinology Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was designed to address this topic and to try to identify possible predictor factors. Among 180 patients with prolactinomas on CAB therapy, the authors selected those who fulfilled very strict criteria, particularly additional CAB therapy for at least 2 years, normalization of serum prolactin (PRL) levels following CAB restart, no tumor remnant >10 mm, no previous pituitary radiotherapy or surgery; and current CAB dose ≤1.0 mg/week. Recurrence was defined as an increase of PRL levels above the upper limit of normal. A total of 34 patients (70.6% female) treated with CAB for 24–30 months were recruited. Ten patients (29.4%) remained without evidence of recurrence after 24–26 months of follow-up. Twenty-four patients (70.6%) recurred within 15 months (75% within 12 months) after drug withdrawal and ~80% were restarted CAB. Median time to recurrence was 10.5 months (range, 3–15). Despite overlapping values, non-recurring patients had significantly lower mean PRL levels before withdrawal. Moreover, the recurrence rate was lower in subjects without visible tumor on pituitary magnetic resonance imaging (MRI) than in those with small remnant tumor (60 vs. 79%), though the difference was not statistically significant (P = 0.20). No other characteristic could be identified as a predictor of successful CAB discontinuation. In conclusion, a second attempt of CAB withdrawal after two additional years of therapy may be successful, particularly in patients with lower PRL levels and no visible tumor on pituitary MRI. Close monitoring of PRL level is mandatory, especially within the first year after withdrawal, where most recurrences are detected. Frontiers Media S.A. 2015-02-04 /pmc/articles/PMC4316769/ /pubmed/25699020 http://dx.doi.org/10.3389/fendo.2015.00011 Text en Copyright © 2015 Vilar, Albuquerque, Gadelha, Rangel Filho, Siqueira, da Fonseca, Viana, Gomes and Lyra. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Vilar, Lucio Albuquerque, José Luciano Gadelha, Patrícia Sampaio Rangel Filho, Frederico Siqueira, Aline Maria C. da Fonseca, Maíra Melo Viana, Karoline Frazão Gomes, Barbara Sales Lyra, Ruy Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? |
title | Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? |
title_full | Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? |
title_fullStr | Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? |
title_full_unstemmed | Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? |
title_short | Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? |
title_sort | second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316769/ https://www.ncbi.nlm.nih.gov/pubmed/25699020 http://dx.doi.org/10.3389/fendo.2015.00011 |
work_keys_str_mv | AT vilarlucio secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT albuquerquejoseluciano secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT gadelhapatriciasampaio secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT rangelfilhofrederico secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT siqueiraalinemariac secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT dafonsecamairamelo secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT vianakarolinefrazao secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT gomesbarbarasales secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile AT lyraruy secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile |